Insys founder John Kapoor has maintained his innocence in the face of charges.
The firm's Narcan product is more than just a lifesaving treatment for opioid overdose. It's a brilliant, salient campaign, as well.
The pharma company manufactures the well-known opioid OxyContin.
FDA approval of Gilead HIV drug prompts ViiV patent suit; Poll shows split in voter reaction to Trump opioid plan; Outcome Health partners with CDC.
FDA releases information on Exondys 51; Sanofi's dengue vaccine faces new restrictions; Kellyanne Conway named opioid czar
Non-profit challenges Gilead's Sovaldi patent; The Medicines Company to cut hundreds of jobs; Amgen ends R&D for experimental CETP drug
FDA briefing document affirms diabetes drug's efficacy; J&J debuts new tools to improve adherence; AZ says cancer drug data was falsified
Cigna will no longer cover OxyContin; the AMA no longer supports price-fixing to lower drug prices; Gottlieb is not in favor of 'right-to-try' laws
The FDA warns drugmaker over opioid promotion; Watson may not be living up to the hype; Merck acquires immuno-oncology biotech
Gottlieb calls for new opioid training for docs; FDA committee to examine Novartis' CAR-T therapy; no Viagra ads expected during NFL season
Insurance companies balk at expensive PCSK9 inhibitors; Publicis to focus investments on AI platform; clinical trial reveals Novartis' eye drug requires less frequent injections
Alkermes lobbies lawmakers on its opioid addiction drug; rep salaries rise; SCOTUS rules in favor of Sandoz in biosimilar suit
The FDA asks Endo to take opioid off the market; Lilly partners with Swiss biotech; House committee advances PDUFA bill — without off-label provision
Oncologists more likely to prescribe drugs when receiving travel, meal payments; Tesaro reportedly considering a sale; AbbVie has best pharma reputation
PBMs' use of "clawbacks" prompt lawsuits; Merck's experimental antiviral drug prevents infection; EMA recommends Novartis' lung-cancer combo drug
Illumina and IBM enter DNA sequencing partnership; J&J to outline price increases in new report; Egalet's opioid Arymo ER gets FDA approval
Vertex drug challenged by low refill rates; the FDA has issued only 4 warning or untitled letters this year; Horizon settles PBM-rebate suit
Some U.S. hospitals still haven't received Valeant discounts; U.N. General Assembly will discuss antibiotic resistance; AstraZeneca diabetes drugs lowered blood sugar in study
The OPDP sent its second untitled letter this week, this time to Durect and Pain Therapeutics over the presentation of Remoxy ER.
Grassley blasts Mylan over EpiPen price increases; Portola Pharmaceuticals receives CRL letter for reversal agent; the FDA approves Pfizer's opioid
OncoGenex's prostate cancer drug fails in clinical trial; Aetna to exit exchanges in 11 states; pregnant women taking acetaminophen have higher risks for their children
IBM develops chip to detect early stages of cancer; Theranos plans to develop a "minilab;" Aetna and Humana to sell $117 million in assets
Pfizer to disclose addiction risk in promo materials for opioids; Medivation considers an acquisition; Almirall expresses interest in buying Valeant drugs
The drugmaker launched a three-part video series that uses humor to address prescription drug abuse.
Purdue Pharma launched a new resource around the abuse-deterrent properties of some of its painkillers.
Court blocks generic competition for Opana ER until 2023; lawmakers question Valeant drug price hikes; Roche's immuno-oncology drug meets primary endpoint in mid-stage trial
Study shows Merck's Januvia does not increase heart risks; a former Genentech exec launches a behavioral health business; lawmakers want black-box warnings on more opioids
Endo agrees to buy Par Pharmaceuticals for $8 billion; AstraZeneca deepens commitment to biologics; FDA cautions that certain diabetes drugs could lead to serious condition
Amarin sues FDA over off-label discussions; spike in HCV infections in US blamed on Endo opioid; Pfizer settles gambling, eating and sex addiction lawsuit
Takeda proposes $2.2-billion settlement to resolve Actos suits; Public Citizen says diabetes drugs are unlawfully promoted; PAIN study says 20% to 30% of opioid drugs are misused